Advertisement
Advertisement
U.S. markets open in 6 hours 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

4D pharma plc (FRPRF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.99000.0000 (0.00%)
At close: 1:17PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9900
Open0.9900
BidN/A x N/A
AskN/A x N/A
Day's Range0.9900 - 0.9900
52 Week Range0.9900 - 2.3000
Volume50,450
Avg. Volume4,459
Market Cap178.498M
Beta (5Y Monthly)2.99
PE Ratio (TTM)N/A
EPS (TTM)-0.6070
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for FRPRF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 4D PHARMA PLC
    Daily – Vickers Top Buyers & Sellers for 10/25/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Business Wire

    4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit

    LEEDS, England, October 12, 2021--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D management will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit being held on October 19, 2021.

  • Business Wire

    4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021

    LEEDS, England, September 15, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces new biomarker analyses from two ongoing clinical trials of its lead immuno-oncology single strain Live Biotherapeutic, MRx0518, in both neoadjuvant and refractory solid tumor settings, at the European Society for Medical Oncology (ESMO) Congress, September 16-21, 202

  • Business Wire

    4D pharma to Participate in Upcoming Virtual Investor Conferences in September

    LEEDS, England, September 09, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will present at the following virtual investor conferences:

Advertisement
Advertisement